Entecavir: A potent new antiviral drug for hepatitis B

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 683-688

  Honkoop, P ^a   de Man, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Entecavir; Hepatitis B; Nucleoside analogue; Review; Treatment

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CIDOFOVIR; CIRCULAR DNA; CLEVUDINE; DEOXYGUANOSINE DERIVATIVE; DNA DIRECTED DNA POLYMERASE GAMMA; ENTECAVIR; FIALURIDINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; LOBUCAVIR; MITOCHONDRIAL DNA; NEW DRUG; NUCLEOSIDE ANALOG; PENCICLOVIR; PLACEBO; TENOFOVIR; VIRUS DNA;

CLINICAL STUDY; CLINICAL TRIAL; COUGHING; DATA ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GROWTH INHIBITION; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER FAILURE; LIVER GRAFT; MYOPATHY; NONHUMAN; PANCREATITIS; PHARYNGITIS; RECIPIENT; REVIEW; VERTIGO; VIRUS ENVELOPE; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; GUANINE; HEPATITIS B; HUMANS;

EID: 0037398391     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.683     Document Type: Review

References (29)

1. WONG DK, CHEUNG AM, O'ROURKE K, NAYLOR CD, DETSKY AS, HEATHCOTE J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. (1993) 119:312-323.
2. LOK AS, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34(6):1225-1241.
3. YAMANAKA G, WILSON T, INNAIMO S et al.: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. (1999) 43(1):190-193.
4. SEIFER M, HAMATAKE RK, COLONNO RJ, STANDRING DN: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. (1998) 42(12):3200-3208.
5. INNAIMO SF, SEIFER M, BISACCHI GS, STANDRING DN, ZAHLER R, COLONNO RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. (1997) 41(7):1444-1448.
6. COLONNO RJ, GENOVESI EV, MEDINA I et al.: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. (2001) 184(10):1236-1245.
7. GENOVESI EV, LAMB L, MEDINA I et al.: Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. (1998) 42(12):3209-3217.
8. MORALEDA G, SAPUTELLI J, ALDRICH CE, AVERETT D, CONDREAY L, MASON WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. (1997) 71(12):9392-9399.
9. DANDRI M, BURDA MR, WILL H, PETERSEN J: Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology (2000) 32:139-146.
10. DANDRI M, BURDA MR, BURKLE A et al.: Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology (2002) 35(1):217-223.
11. ZHOU T, SAPUTELLI J, ALDRICH CE, DESLAURIERS M, CONDREAY LD, MASON WS: Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob. Agents Chemother. (1999) 43(8):1947-1954.
12. MARION PL, SALAZAR FH, WINTERS MA, COLONNO RJ: Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. (2002) 46(1):82-88.
13. MCKENZIE R, FRIED MW, SALLIE R et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. (1995) 333:1099-1105.
14. HONKOOP P, SCHOLTE HR, DE MAN RA, SCHALM SW: Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf. (1997) 17(1):1-7.
15. BRISTOL-MYERS SQUIBB: Data on file (2001).
16. DE MAN RA, WOLTERS LM, NEVENS F et al.: Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 34(3):578-582.
17. HONKOOP P, DE MAN RA, HEIJTINK RA, SCHALM SW: Hepatitis B reactivation after lamivudine. Lancet (1995) 346(8983):1156-1157.
18. HONKOOP P, DE MAN RA, NIESTERS HG, ZONDERVAN PE, SCHALM SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 32(3):635-639.
19. WOLTERS LM, HANSEN BE, NIESTERS HG, DEHERTOGH D, DE MAN RA: Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J. Hepatol. (2002) 37(1):137-144.
20. NEVENS F, DE MAN RA, CHUA D et al.: Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B. Hepatology (2000) 32:A869.
21. LAI CL, ROSMAWATI M, LAO J et al.: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 123(6):1831-1838.
22. HONKOOP P, NIESTERS HG, DE MAN RA, OSTERHAUS AD, SCHALM SW: Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. (1997) 26(6):1393-1395.
23. LAI CL: Antiviral therapy for hepatitis B and C in Asians. J. Gastroenterol. Hepatol. (1999) 14(Suppl.):S19-S21.
24. NIESTERS HG, DE MAN RA, PAS SD, FRIES E, OSTERHAUS AD: Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J. Med. Microbiol. (2002) 51(8):695-699.
25. ONO SK, KATO N, SHIRATORI Y et al.: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. (2001) 107:449-455.
26. LEVINE S, HERNANDEZ D, YAMANAKA G et al.: Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In vitro. Antimicrob. Agents Chemother. (2002) 46(8):2525-2532.
27. CHANG TT, HADZIYANNIS S, CIANCIARA J et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology (2002) 36:A550.
28. PERRILLO R, SCHIFF ER, YOSHIDA E et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology (2000) 32:129-134.
29. SHAKIL A, LILLY L, ANGUS P et al.: Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for HBV. J. Hepatol (2002) 36:122.